Syros Pharmaceuticals’ (SYRS) shares were higher 5% in recent pre-market trade after the company said the biomarker status of patients screened for a phase 2 trial of SY-1425 in genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, was predictive of myeloid cell differentiation in the patients’ blood samples treated ex vivo with SY-1425.
The company said the data support the clinical utility of the biomarker test for patient selection.
The phase 2 clinical trial is assessing the safety and efficacy of SY-1425 as a monotherapy and in combination with azacitidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patient populations.
“These findings validate our platform’s ability to select patients we believe may be most likely to respond to gene control therapies such as SY-1425. We found the RARA or IRF8 biomarkers in a significant portion of patients screened to date for the phase 2 clinical trial and believe there remains a high unmet need for better treatment options for these AML and MDS patients,” said David Roth, chief medical officer.